enVVeno Medical Corporation

NVNO

US29415J1060

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 21:00:00 31/05/2024 BST			5-day change	1st Jan Change
4.77 ^USD	-1.04%		-4.79%	-7.20%

05-08	EnVVeno Medical Corporation Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
04-16	EnVVeno Medical Corporation Announces Additional Topline Efficacy Data from the VenoValve U.S. Pivotal Trial to Be Presented at the 46th Annual Charing Cross Symposium on April 24, 2024	CI

Hancock Jaffe Laboratories, Inc will Change its Name to enVVeno Medical Corporation

October 01, 2021 at 05:00 am

Effective October 01, 2021, Hancock Jaffe Laboratories, Inc will change its name to enVVeno Medical Corporation.

Latest news about enVVeno Medical Corporation

EnVVeno Medical Corporation Reports Earnings Results for the First Quarter Ended March 31, 2024	05-08	CI
EnVVeno Medical Corporation Announces Additional Topline Efficacy Data from the VenoValve U.S. Pivotal Trial to Be Presented at the 46th Annual Charing Cross Symposium on April 24, 2024	04-16	CI
EnVVeno Medical Corporation Appoints Andrew Cormack as Its Chief Commercial Officer	04-09	CI
EnVVeno Announces Positive Topline Efficacy Data for VenoValve US Pivotal Trial	03-06	MT
EnVVeno Medical Corporation Announces the Presentation of Positive Topline Efficacy Data Showing Significant Clinical Improvement from the Savve U.S. Pivotal Trial for the Venovalve	03-06	CI
EnVVeno Medical Corporation Reports Earnings Results for the Full Year Ended December 31, 2023	02-29	CI
EnVVeno Medical Corporation Presents Positive Preliminary Device Related Material Adverse Event Data from the VenoValve Pivotal Trial at the 50th Annual VEITH Symposium	11-16	CI
EnVVeno Medical Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	26/10/23	CI
EnVVeno Achieves Full Enrollment for VenoValve Trial; to Conduct Preclinical Trial of Another Venous Valve Product	06/10/23	MT
EnVVeno Medical Corporation Achieves Full Enrollment for VenoValve U.S. Pivotal Trial	06/10/23	CI
EnVVeno Medical Corporation announced that it expects to receive $27.997135 million in funding	05/10/23	CI
EnVVeno Medical Corporation Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	31/07/23	CI
Envveno Medical Corporation Provides Enrollment Update for Ongoing VenoValve(R) U.S. Pivotal Study	05/07/23	CI
EnVVeno Medical Corporation(NasdaqCM:NVNO) added to Russell 3000E Growth Index	23/06/23	CI
EnVVeno Medical Corporation(NasdaqCM:NVNO) added to Russell Microcap Growth Index	23/06/23	CI
EnVVeno Medical Corporation Reports Earnings Results for the First Quarter Ended March 31, 2023	28/04/23	CI
EnVVeno Medical Corporation Reports Earnings Results for the Full Year Ended December 31, 2022	02/03/23	CI
Envveno Medical Promotes Hamed Alavi to Senior Vice President and Chief Technology Officer	18/01/23	CI
Envveno Medical Corporation Presents Positive Long-Term, Three-Year Observational Data from A Cohort of Patients That Participated in the Previously Concluded Venovalve First-In-Human Clinical Tria	17/11/22	CI
EnVVeno Medical Successfully Passes Preliminary FDA Safety Review for the VenoValve U.S. Pivotal Study	07/11/22	CI
EnVVeno Medical Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	27/10/22	CI
EnVVeno Medical Corporation Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	03/08/22	CI
EnVVeno Medical Corporation Reports Earnings Results for the First Quarter Ended March 31, 2022	29/04/22	CI
EnVVeno Medical Secures US Patent for Manufacturing Method Related to VenoValve	11/04/22	MT
EnVVeno Medical Corporation Reports Earnings Results for the Full Year Ended December 31, 2021	28/03/22	CI

Chart enVVeno Medical Corporation

Duration

Period

More charts

enVVeno Medical Corporation is a late-stage clinical med-tech company. The Company is focused on the advancement of bioprosthetic (tissue-based) solutions to improve the standard of care for the treatment of venous disease. The Company is developing surgical and non-surgical replacement venous valves for patients suffering from severe Chronic Venous Insufficiency (CVI) of the deep venous system of the leg. The Company's lead product, VenoValve, which is a porcine based replacement venous valve developed to surgically implanted in the deep venous system of the leg to treat severe CVI. The VenoValve is implanted into the femoral vein of the patient in an open surgical procedure via a five-to-six-inch incision in the upper thigh. The VenoValve is being evaluated in the surgical anti-reflux venous valve endoprosthesis (SAVVE) United States clinical trial. The Company is also developing a second product called enVVe, which is a non-surgical, transcatheter based replacement venous valve.

Sector

Biotechnology & Medical Research

Calendar

06/11/2024 - Q3 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

4.77 USD

Average target price

20.4 USD

Spread / Average Target

+327.67%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
ENVVENO MEDICAL CORPORATION	-7.20%	63.58M
MODERNA, INC.	+43.36%	54.64B
IQVIA HOLDINGS INC.	-5.31%	39.92B
LONZA GROUP AG	+37.52%	38.82B
ICON PUBLIC LIMITED COMPANY	+14.75%	26.86B
CELLTRION, INC.	-12.56%	26.22B
ALNYLAM PHARMACEUTICALS, INC.	-22.45%	18.78B
BIO-TECHNE CORPORATION	+0.04%	12.16B
UNITED THERAPEUTICS CORPORATION	+25.12%	12.21B
MEDPACE HOLDINGS, INC.	+26.04%	11.94B

Other Biotechnology & Medical Research

enVVeno Medical Corporation

Equities

NVNO

US29415J1060

Biotechnology & Medical Research

Hancock Jaffe Laboratories, Inc will Change its Name to enVVeno Medical Corporation

Latest news about enVVeno Medical Corporation

Chart enVVeno Medical Corporation

Company Profile

Income Statement Evolution

Analysts' Consensus

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Other Biotechnology & Medical Research